{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
NeurAxis, Inc.
NeurAxis, Inc. Hits New 52-Week High at USD 7.34
NeurAxis, Inc. has achieved a new 52-week high of USD 7.34, significantly up from its low of USD 1.33. With a market cap of USD 59 million, the company faces challenges, including a negative return on equity and a high price-to-book ratio, reflecting its competitive industry landscape.
NeurAxis, Inc. Hits New 52-Week High of $6.60, Up 116.1%
NeurAxis, Inc. has achieved a new 52-week high of USD 6.60, reflecting a substantial increase over the past year. With a market capitalization of USD 59 million, the company operates in a competitive biotechnology sector, despite currently facing financial challenges, including a negative P/E ratio and significant losses.
NeurAxis, Inc. Hits New 52-Week High of $6.35, Up 98.97%
NeurAxis, Inc. has achieved a new 52-week high, reflecting a substantial increase over the past year and significantly outperforming the S&P 500. With a market capitalization of USD 59 million, the company operates in a competitive sector, though it currently faces financial challenges, including losses and a negative return on equity.
NeurAxis, Inc. Hits New 52-Week High of $6.30, Up 115.75%
NeurAxis, Inc. has achieved a new 52-week high of USD 6.30, reflecting a substantial increase over the past year. With a market capitalization of USD 59 million, the company operates in a competitive biotechnology sector, despite currently facing financial challenges, including a negative P/E ratio and significant losses.
Is NeurAxis, Inc. technically bullish or bearish?
As of September 8, 2025, NeurAxis, Inc. has a neutral technical trend with mixed indicators, showing mild bearishness in MACD and KST, while outperforming the S&P 500 in the short term but declining 10.62% over the past year compared to the S&P's 17.14% gain.
Is NeurAxis, Inc. technically bullish or bearish?
As of June 2, 2025, the market trend has shifted to mildly bearish, driven by a bearish RSI and moving averages, despite a mildly bullish MACD, indicating overall bearish sentiment due to recent declines.
What does NeurAxis, Inc. do?
NeurAxis, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $2 million as of March 2025, with a market cap of $18.16 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -840.97%.
How big is NeurAxis, Inc.?
As of Jun 18, NeurAxis, Inc. has a market capitalization of 18.16 million, with net sales of 2.94 million and a net profit of -8.41 million over the last four quarters. Shareholder's funds are 2.07 million, and total assets are 4.76 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
